Being able to model human disorders in zebrafish allows scientists to understand the molecular basis of disease. This may ultimately increase the efficiency and power of the drug discovery process, thus bringing new medicines to the market faster and cheaper.”

Dr. Roger Cone
Znomics Founder and Chief Scientific Officer
Regarding study published in The FASEB Journal, July 2007

Accelerating Drug Discovery

Despite several decades of extraordinary advances in biotechnology, it has become increasingly more difficult and expensive to bring new drugs to market to treat human disorders and diseases.

The Znomics Drug Discovery Platform delivers an innovative approach to whole animal compound screening that is less costly, faster and more powerful than traditional single-target screening for drug discovery.

The ZeneMark® Library of mutant fish lines provides foundation technology for discovering new drug targets, creating human disease models and conducting high-throughput in vivo screening in zebrafish (Danio rerio).

[Learn more about Znomics...]

Znomics News

May 8, 2008
Znomics and University of Utah Launch Collaborative Drug Discovery Program in Oncology, Autoimmune Disease and Inflammation. [Read more...]

April 16, 2008
Znomics Launches Drug Discovery Program in Obesity Using Proprietary In Vivo Screening Model. [Read more...]

March 6, 2008
Znomics announced the appointment of Stephane Berghmans, D.V.M., Ph.D. to Director of Drug Discovery, effective March 10, 2008. [Read more...]

[Read more Znomics news...]